Atterx Biotherapeutics is a specialty pharmaceutical company dedicated to developing innovative products to prevent and treat antibiotic-resistant bacterial infections. With the alarming rise of antibiotic resistance, Atterx recognizes the need for novel solutions in the fight against infections that were once easily treatable. One of Atterx's promising advancements is C-1205, a product utilizing bacterial interference technology to prevent catheter-associated urinary tract infections.

Currently, Atterx has an IND (Investigational New Drug) on file with the FDA and is preparing to enter combined Phase I/II clinical trials. Additionally, Atterx is developing GN-4474, which utilizes the natural process of bacterial conjugation to treat infections caused by Gram-negative bacteria. Animal infection models have shown its effectiveness, and an IND filing is expected in 2024.

Given the urgent threat posed by multi-drug resistant infections, both the US and the EU have declared them national threats. Atterx is leveraging the market incentives introduced by the GAIN Act of 2012 to expedite the development and approval of new antibiotics. Backed by an experienced management team with extensive expertise in the pharmaceutical industry, Atterx is poised to make a significant impact in combating antibiotic resistance and protecting lives worldwide